Claims

1. A pharmaceutical composition for preventing or treating viral infectious diseases comprising a compound represented by the following general formula (I):

5 (wherein

15

20

25

A represents a phenyl group substituted with -OX, or a 3-indolyl group;

X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms;

B represents a hydrogen atom, a hydroxyl group, an oxo group,  $-N(R^4)(R^5)$ , =N-OH,  $=N-OR^6$  or a halogen atom;

 $R^4$  and  $R^5$  may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or  $R^4$  and  $R^5$  together represent a 3 to 8 membered ring;

 $R^6$  represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms);

D represents a hydrogen atom or a hydroxyl group; bond E represents a single bond or double bond;  $R^1$ ,  $R^2$  and  $R^3$  may be the same or different, and each

represent a hydrogen atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms) a prodrug thereof or a pharmaceutically acceptable salt thereof.

The pharmaceutical composition according to claim 1 comprising the compound of formula (I) according to claim 1 represented by the following general formula (I'), a prodrug thereof or a pharmaceutically acceptable salt thereof:

20

(wherein A, B, D, bond E,  $R^1$ ,  $R^2$  and  $R^3$  are the same as defined in claim 1).

3. The pharmaceutical composition according to claim 1
25 or 2 comprising a compound of formula (I), a prodrug
thereof or a pharmaceutically acceptable salt thereof
wherein A represents a phenyl group substituted with -OX
at position 4, X represents a hydrogen atom, a linear or

branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms.

5

10

15

- 4. The pharmaceutical composition according to any one of claims 1 to 3 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein B represents an oxo group, a hydrogen atom, a hydroxyl group or  $=N-OR^6$ .
- 5. The pharmaceutical composition according to any one of claims 1 to 4 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein  $R^1$ ,  $R^2$  and  $R^3$  may be the same or different and each represent a hydroxyl group, an amino group, or OZ (wherein Z represents a linear or branched alkyl group having 1 to 4 carbon atoms).
- The pharmaceutical composition according to claim 1 20 or 2 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein A represents a phenyl group substituted with -OX at position 4, X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear 25 or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon atoms, B represents an oxo group, a hydroxyl group or =N- $OR^6$ , and  $R^1$ ,  $R^2$  and  $R^3$  may be the same or different and each represent a hydroxyl group or -OZ (wherein Z 30 represents a linear or branched alkyl group having 1 to 4 carbon atoms).
- 7. The pharmaceutical composition according to claim 6 35 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein X

represents a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon atoms, B represents an oxo group or a hydroxyl group, and  $R^1$ ,  $R^2$  and  $R^3$  each represent a hydroxyl group.

- 8. The pharmaceutical composition according to claim 1 or 2 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein A represents a 3-indolyl group.
- 9. The pharmaceutical composition according to claim 8 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein B represents an oxo group or a hydroxyl group, and R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each represent a hydroxyl group.
- 10. The pharmaceutical composition according to claim 1
  20 or 2 comprising a compound of formula (I), a prodrug
  thereof of a pharmaceutically acceptable salt thereof,
  selected from the compounds indicated below.

or

5

11. The pharmaceutical composition according to claim 1 or 2 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, selected from the compounds indicated below.

No.6

No.1

No.3

HO HO NOCH<sub>3</sub>

No.15

12. The pharmaceutical composition according to claim 1 or 2 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, selected from the compounds indicated below.

13. The pharmaceutical composition according to any one of claims 1 to 12, wherein the viral infectious disease is HCV infection.

or

5

- 14. The pharmaceutical composition according to claim 13, wherein the HCV infection is hepatitis C.
- 15. A compound represented by the following general
  5 formula (I):

(wherein

10

15

20

25

A represents a phenyl group substituted with -OX; X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms;

B represents a hydrogen atom, a hydroxyl group, an oxo group,  $-N\left(R^4\right)\left(R^5\right)$ , =N-OH,  $=N-OR^6$  or a halogen atom;

 $R^4$  and  $R^5$  may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or  $R^4$  and  $R^5$  together represent a 3 to 8 membered ring;

R<sup>6</sup> represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms);

D represents a hydrogen atom or a hydroxyl group; bond E represents a single bond or double bond;  $R^1$ ,  $R^2$  and  $R^3$  may be the same or different, and each

represent a hydrogen atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched 10 alkynyl group having 2 to 4 carbon atoms, with the proviso that the case in which A is a phenyl group substituted with -OX at the p position, X is a 2-isopentenyl group or a hydrogen atom, B is an oxo group, D is a hydrogen atom, E represents a double bond, and all of R<sup>1</sup> to R<sup>3</sup> are a 15 hydroxyl group, and the case in which A is a phenyl group substituted with -OX at position p, X is a 2-isopentenyl group, B is an oxo group, D is a hydrogen atom, bond E represents a double bond, and all of R1 to R3 are a methoxy group are excluded) a prodrug thereof or a pharmaceutically acceptable salt thereof.

A compound represented by the following general 25 formula (I):

(wherein

20

A represents a phenyl group substituted with -OX; X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms;

5

10

15

20

25

30

35

B represents a hydrogen atom, a hydroxyl group, an oxo group,  $-N(R^4)(R^5)$ , =N-OH,  $=N-OR^6$  or a halogen atom;

 $R^4$  and  $R^5$  may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or  $R^4$  and  $R^5$  together represent a 3 to 8 membered ring;

R<sup>6</sup> represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms);

D represents a hydrogen atom or a hydroxyl group; bond E represents a single bond or double bond;

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> may be the same or different, and each represent a hydrogen atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms, with the proviso that the case in which A is a phenyl group substituted with -OX at position p and X is a hydrogen atom, and the case in which A is a phenyl group substituted with -OX at position p, X is a 2-isopentenyl group, B is an oxo group, D is a hydrogen atom, bond E indicates a double bond, and

all of  $R^1$  to  $R^3$  are a hydroxyl group or a methoxy group are excluded)

a prodrug thereof or a pharmaceutically acceptable salt thereof.

5

17. The compound of formula (I) according to claim 15 or 16 represented by the following general formula (I'), a prodrug thereof or a pharmaceutically acceptable salt thereof:

10

(wherein X, B, D, bond E,  $R^1$ ,  $R^2$  and  $R^3$  are the same as described in claim 15).

- 18. The compound of formula (I) according to claims 15 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein X represents a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon 20 atoms, and B represents a hydroxyl group, an oxo group or =N-OR<sup>6</sup>.
- 19. The compound of formula (I) according to any one of claims 15 to 18 represented by the following formula, a prodrug thereof or a pharmaceutically acceptable salt thereof.

No.14

20. The compound of formula (I) according to any one of claims 15 to 18 represented by the following formula, a prodrug thereof or a pharmaceutically acceptable salt thereof.

- 21. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 15 to 20, a prodrug thereof or a pharmaceutically acceptable salt thereof.
  - 22. The pharmaceutical composition according to claim

- 21 for preventing or treating of viral infectious diseases.
- 23. The pharmaceutical composition according to claim
- 22, wherein the viral infectious disease is HCV infection.

5

- 24. The pharmaceutical composition according to claim
- 23, wherein the HCV infection is hepatitis C.